This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Centre Leon Berard, University Claude Bernard - Lyon 1. Active years: 2014.
Company Filing History:
1 out of 39 
1 out of 215 
Years Active: 2014
Title: Pascale Cohen: Innovator in Cancer Prognostics
Introduction
Pascale Cohen is a notable inventor based in Lyon, France. He has made significant contributions to the field of cancer research, particularly in the development of prognostic biomarkers. His work focuses on improving the understanding of cancer progression and recurrence.
Latest Patents
Cohen holds a patent for ZNF217, which serves as a new prognostic and predictive biomarker for recurrent invasive and metastatic phenotypes in breast cancer. The present invention relates to methods for determining the prognosis of cancer. These methods involve assessing the level of expression of the ZNF217 gene in cancer cell samples or tumor samples. Over-expression of ZNF217 is correlated with a higher likelihood of metastasis and an increased chance of cancer relapse or recurrence.
Career Highlights
Throughout his career, Pascale Cohen has worked with esteemed institutions such as Centre Léon Bérard and University Claude Bernard - Lyon 1. His research has been pivotal in advancing the understanding of cancer biology and improving patient outcomes.
Collaborations
Cohen has collaborated with notable colleagues, including Julie Vendrell and Pierre Roux. These partnerships have enriched his research and contributed to the development of innovative cancer prognostic methods.
Conclusion
Pascale Cohen's work in cancer research exemplifies the impact of innovative thinking in medical science. His contributions, particularly through his patent on ZNF217, highlight the importance of biomarkers in understanding cancer prognosis and treatment.